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ABSTRACT 
 
 
Increasing Expression of Hepatitis B Surface Antigen in Maize through Breeding 
Erin Suzanne Miller 
 
The hepatitis B virus (HBV) is a common virus, with two billion people infected 
worldwide.  It causes approximately 600,000 deaths each year, despite the availability of 
an effective vaccine since 1982.  Maize as a platform for oral vaccination can supply a 
heat stable vaccine, which does not require syringes or trained personnel to administer.  
The Hepatitis B Surface antigen was transformed into maize and this seed was used to 
evaluate expression levels through the breeding process.  The transgene was transferred 
into two elite maize inbreds by backcrossing.  Highest expressing ears were selected each 
generation until approximately 99% commercial parent was obtained with a single gene 
coding for the vaccine present.  Selected individuals were crossed to create hybrid plants.  
This work was done to create high expressing high yielding lines that could be used as a 
plant-based oral vaccine for Hepatitis B.    
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CHAPTER 1 
Literature Review 
Introduction 
 The hepatitis B virus (HBV) is a common virus, with two billion people infected 
worldwide.  It causes approximately 600,000 deaths each year, despite the availability of 
an effective vaccine since 1982.  Chronic infection with HBV can be life-threatening 
causing liver failure due to cirrhosis of the liver, and liver cancer (WHO, 2012).  A heat 
stable oral vaccination would be easier to administer than a traditional vaccine in those 
areas where HBV is most prevalent.  In developing parts of the world, vaccinations are 
not easily accessible; they require proper storage, safe vaccination conditions, and 
properly trained medical personnel.  A method of vaccination that eliminates most of 
these problems could reduce the number of people who contract hepatitis B and suffer 
from the painful symptoms of a chronic or acute infection (WHO, 2012).  
Diagnosis is accomplished by blood tests, which may determine a chronic, or 
acute infection.  Blood tests identify the hepatitis B surface antigen (HBsAg), indicating 
patients with an active infection.  Acute infections have no specific treatment but 
maintaining balanced nutrition, and hydration may help ease symptoms.  The core 
antigen (HBcAg) is another indicator of infection; a positive core antigen test and HBsAg 
test usually suggests a chronic infection. Chronic infections can be treated with 
medications such as interferon and antivirals, but these are not practical in developing 
countries because of cost and lack of availability of the medication. When the virus 
causes liver cancer, surgery and chemotherapy can extend life for several years, but those 
in developing countries typically die soon after diagnosis.  With infection levels around 
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30% worldwide a more practical solution must be found for vaccine administration 
(WHO, 2012). 
Plant Based Oral Vaccinations 
Plant based oral vaccine candidates are created by introducing DNA into the plant 
genome. The DNA contains sequences designed to express a protein that may function as 
a subunit vaccine.  Plant-derived oral vaccines may be safer than traditional recombinant 
vaccines because they eliminate the risk of exposure to animal-derived contaminants.  In 
the development of a vaccine, the subunit protein is considered a candidate vaccine and if 
approved will become a vaccine.  Most vaccines require cold storage and injection 
equipment whereas some plant-based oral vaccines have shown heat stability eliminating 
the need for a cold chain (Lamphear, 2002).   
 Maize as a platform for oral vaccination can supply an efficacious powerful, 
successful vaccine, which is more stable in percent total soluble protein (%TSP) and does 
not require syringes or trained personnel to administer (Lamphear, 2002).  The maize 
seed anatomy allows an ideal environment for a vaccination because it is a naturally bio-
encapsulated environment with a high concentration of protease inhibitors, low moisture 
and high concentration of carbohydrates.  These factors lead to stability during storage 
and allow some antigen to survive the gastrointestinal tract that results in an immunologic 
response.  Encapsulation may also help with thermostability of the antigen, which in turn 
keeps transportation and storage costs low (Hayden, 2012a).  Many different diseases 
could be greatly reduced with plant based oral vaccinations.  But expression levels need 
to be high for effective oral vaccination (Kirk, 2005). 
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 Plant based oral vaccinations have been used to protect against systemic 
intoxication by Shiga toxin Type 2. The Shiga toxin, which is in the bacteria group of E. 
coli, causing kidney failure in children and hemolytic uremic syndrome in adults.  The 
vaccine was produced by destabilizing Shiga toxin A2 (StxA2) using mutagens and a 
plant optimized StxA2 was produced using the polymerase chain reaction and 
transforming this construct into tobacco using Agrobacterium-mediated transformation. 
Each plant was screened for the expression of this toxoid.  Once toxoid expression was at 
high enough levels, mice were fed the oral vaccine and screened for the presence of a 
response by analyzing the immunoglobulin A (IgA), an antibody in the mucosal linings, 
and immunoglobulin G (IgG), an antibody in the blood.  The immunoglobulin levels in 
the mice that received the vaccine determine if the vaccine triggered a response.  This 
oral delivery method of a plant produced candidate vaccine was shown to be effective 
against the Shiga toxin (Wen, 2006).  
 A plant-based oral vaccine for hepatitis B has been produced in maize, with the 
maize producing the hepatitis B surface antigen in the embryo.  Hayden et al created a 
construct, designated HBE, with a globulin 1 promoter sequence, which expresses 
preferentially in the embryo with expression levels of over 0.08% TSP from single seed 
analysis.  Another backcross was performed, this time to an elite line to introduce 
commercial traits.   Each plant was then self-pollinated for two generations to create 
homozygous lines that were used to create hybrids.  The % TSP of individual hybrid seed 
was as high as 0.46% and once bulked, expression was 0.20% TSP.  These results were 
based on whole seed estimates but since the protein production was enriched in the 
embryo, removing the embryo from the whole seed created a more concentrated product.   
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 After testing just the embryo, dry weight concentration increased 6-fold, 
ultimately creating a large increase when comparing whole seed to embryo.  When 
administered to mice, serum IgG showed a large increase with each boost as is expected 
to see with the injected candidate vaccine.  This research shows the usefulness of 
recombinant technology as well as breeding and processing for the production of a heat 
stable, effective vaccine against hepatitis B (Hayden, 2012b).  
 A heat stable plant-based oral vaccine could greatly reduce the number of people 
infected with HBV.  Molecular constructs were made to express HBsAg within the seed.  
Research by Hayden et al (2012a) showed that through plant breeding, the expression 
level can be increased to levels that produce an immune response in mice.  A maize 
variety that has high expression of the HBsAg antigen can be used to safely deliver the 
hepatitis B vaccine to many parts of the world that have difficulty giving standard 
injections. 
 
Hepatitis B Vaccines Currently Available 
 Currently there are several registered vaccines for hepatitis B in the United States, 
two for children and the other a combination vaccine for Hepatitis A and B safe only for 
adults.  Engerix-B is registered from birth through 19 years old with a series of 3 
injections intramuscularly at 0, 1, and 6 months with a dose of 10 micrograms (µcg) 
(FDA, 1989).   Adults over 19 years old should be given three injections of a higher dose 
of 20 mcg at 0, 1, and 6 months.   For those at higher risk of exposure to the virus an 
additional dose at 12 months can be added.  Allergic reactions have been reported and 
they vary from anaphylaxis, fainting, and apnea with the most common problem being 
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soreness at the injection site and fatigue.  The preferred injection site is the front-outside 
part of the thigh for infants and for older children the deltoid is used.  This injection is not 
to be used in the gluteral regions since an adverse response may occur (FDA, 1989). 
 Recombivax HB is another vaccine registered for both adults and infants and is a 
non-infectious subunit viral vaccine in the protein coat. To make this vaccine, HBsAg is 
cloned into yeast and the vaccine is produced from cultures of the recombinant yeast 
strain.  The antigen is harvested and then undergoes a fermentation process which 
involves Saccharomyces cerevisiae which has the genes for the adw subtype of HBsAg 
and grows in yeast, soy peptone, dextrose, amino acids, and mineral salts.  After more 
purification the final dose contains less than 1% yeast protein (Merck, 1983).  A benefit 
to using this method is that the final product does not contain human blood or blood 
products and each batch is tested for sterility.  There are three dosage levels: pediatric/ 
adolescent, adult, and dialysis.  The pediatric/ adolescent dose is 10mcg, and the adult 
dose is 20 mcg.  This vaccine is to be injected intramuscularly with a 3 dose schedule of 
month 0, 1, and 6. Adolescents age 11-15 can receive a 2 dose regime with a higher dose 
at month 0, and 4-6 months later (Merck, 1983).  
 
Ideal Vaccine 
 An ideal vaccine must have each of the following traits: low cost, ease of 
administration, high safety profile, high potency, ease of storage and shipping, stability at 
room temperature, and low allergenicity.  Maize as an oral vaccination is very promising, 
due to its high digestibility in humans, and its low potential as an allergen (Hayden, 
2012b).   It is highly unlikely that introducing one gene would cause maize to be more 
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allergenic than it is currently (Ramessar, 2008).  An allergic reaction to maize is rare and 
only occurs in a small percentage of humans but the reaction can be severe (Food, 2013).  
Traditional yeast-derived vaccines may also cause a severe allergic reactions in 
approximately one in 600,000 doses (Offit, 2013).  
 Maize can be grown in most parts of the world which allows for regions to grow 
their own crop to match local demand for a plant-based pharmaceutical. Maize grows 
quickly, has high yields, can be shipped easily without the need for cold storage, and 
maize has ‘generally regarded as safe’ (GRAS) status by the Food and Drug 
Administration (FDA) (Ramessar, 2008). Maize may also have multiple antigens inserted 
into the genome allowing for more than one pathogen to be targeted. Alternatively, many 
different maize lines can be blended to combine different antigens in one maize bulk to 
create multi-use oral vaccines (Lamphear, 2002).     
 
Maize-Based Oral Vaccine 
Cost  
 Vaccines could be grown in commercially available maize lines, allowing for 
large scale production, reducing total cost.  Antigens expressed in the seed may remain 
stable inside the grain, removing need for refrigeration.  The potential exists that a 
combination of transgenic lines could be created to produce a combination vaccine 
(Streatfield, 2001).  With a combination vaccine fewer items would be shipped, 
refrigerated, and administered, further lessening cost.  Another way to reduce the cost is 
to lessen or delete the need for the cold chain.  Maintaining cold storage costs the world 
200-300 million dollars per year (Giudice, 2006).  As an example, avidin, a protein in 
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eggs that binds biotin and is used in many diagnostic tests, was genetically inserted into 
maize.   The protein produced in plants was equivalent to that found in chicken eggs but 
at a much lower cost than production in eggs.  The grain could be stored for years without 
losing activity and because the animal was removed there is no chance of contaminating 
workers with salmonella (Howard, 2005).   
 
Risks  
 One common concern is the potential contamination of the food supply with 
products that are not intended for the food supply.  Both the Food and Drug 
Administration (FDA) and the United States Department of Agriculture (USDA) have 
compiled a set of regulations designed to maintain food safety with an increase in the 
production of plant-based pharmaceutical crops.  Other possible risks include the 
allergenic potential of maize, and how the introduction of the transgene may produce 
different post translational products that may produce a new allergen.  The Cartagena 
Protocol on Biosafety was created and adopted by many countries to standardize risk 
management for many products including plant based oral vaccines (Nap, 2003).  
Vertical gene transfer is avoided by having large buffer areas between pharmaceutical 
crops and food crops of the same species.  Regulations state that a pharmaceutical crop 
must be at least one mile away from another crop of the same species (Becker, 2005).  
This buffer zone is effective in maize because maize has short-lived pollen, a short 
dispersal range, and no wild relatives in North America (Ramessar, 2008).  
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Distribution 
Plants store proteins naturally, by using tissues of the plant that are able to store high 
amounts of protein without degradation would reduce the need for refrigeration, thus 
reducing transportation and storage costs (Streatfield, 2001). The drying of seed results in 
the long term storage ability at ambient temperatures (Rybicki, 2009).  Hayden et al 
stored maize seed with HBsAg at different temperatures for a month at -20°C and 55°C 
and found no decrease in expression with oil-extracted samples and the conclusion was 
made that HBsAg does not decrease in oil-extracted samples at 55°C for an extended 
amount of time (2012 a).  Also, there are fewer problems with biological safety since 
there are no viral or human pathogens in plants therefore only simple storage is needed 
with no need for cold storage (Shchelkunov, 2010). 
 
Regulations  
 The USDA oversees the production and transport of transgenic material, with a 
focus on minimizing genetic transfer, done through containment.  To prevent genetic 
transfer buffer zones are kept between transgenic and non-transgenic crops of the same 
variety, eliminating the possibility of cross pollination.  If the physical buffer zone cannot 
be achieved, a temporal buffer can be created by planting weeks apart so the reproductive 
stage of one field would be different than the other.  At harvest this is maintained by 
utilizing separate equipment for transgenic and non-transgenic crops as well as separate 
secure locations for storage, and transportation (Kirk, 2005).  
 The FDA regulates the pharmaceutical aspect of the crop in testing, creating the 
product, and the sale of the edible vaccine.  Good Laboratory Practices (GLP) and Good 
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Manufacturing Practices (GMP) have been created to merge both risk management 
practices and production methods to reduce the possibility of contamination and to 
minimize risks of the pharmaceutical material getting into a food source.  Both the FDA 
and USDA will have to work in conjunction to cover the different sectors that each 
branch oversees (Kirk, 2005).  
 
Plant-Based Oral Vaccine Example 
 An edible subunit vaccine against strains of enterotoxigenic E. coli was created in 
maize.  The LT-B gene of E. coli and cholera toxin B have proven to confer protection 
against E. coli in mice.  Transformations were done to immature embryos of Hi-II and the 
T0 plants were planted in a greenhouse (Streatfield, 2002).  Hi-II is a line of maize that is 
known to have good embryos for transformation but low agronomic qualities (Armstrong, 
1991).  T1 seed was planted in a field and a selection spray of 1% glufosinate ammonium 
was used to separate the transgenic plants from the non-transgenic plants.  The T1 plants 
were crossed with two elite inbred lines, one a Lancaster and the other a Stiff Stalk to 
produce T2 lines.  Hybrids were created when the two elite lines containing the transgene 
were crosses. To determine the amount of vaccine present in the seed, one seed was 
ground, and an ELISA assay conducted to determine the percent of total soluble protein 
(%TSP) which translates into the concentration of antigen present in the seed.  Through 
plant breeding the lines improved in both agronomic traits and the amount of vaccine 
present.  The T1 lines expressed 0.013 to 1.8 %TSP while the T3 line expressed 9.2% 
TSP, a five-fold increase (Streatfield, 2002).  
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Conclusion 
Hepatitis B is easily transmitted through blood, bodily fluids, perinatal infection, 
sexual contact, and unsafe injections.   HBV is 50 to 100 times more infectious than HIV, 
and can survive outside the body for seven days.  Once the virus infects a host, there is 
typically an incubation period of 90 days.  To prevent the spread of hepatitis B, children 
are vaccinated within the first day of life, with a typical vaccination administered in three 
doses.   Following vaccination, children show a 95% antibody response while adults 
show a 90% antibody response.  When those individuals who are non-responders are 
given an extra boost 30-50% of them become responders (Kwon, 2011).  Once 
vaccinated, the protection provided lasts at least 20 years and possibly lifelong.  
Currently 179 of 196 countries have hepatitis B as part of their vaccination schedules, 
which in many countries has reduced the rate of chronic infections in children to 1% 
compared to an 8-15% infection rate before the vaccination (WHO, 2012). Many 
developing countries are not able to administer the vaccination because it is expensive, 
and requires cold storage.  They also lack the ability to administer critical booster 
vaccinations, as well as provide trained personnel to administer the injection following 
sterile procedures. 
An acute infection presents itself with jaundice, dark urine, tiredness, nausea, 
vomiting and abdominal pain while those who have an advanced chronic infection 
develop cirrhosis of the liver or liver cancer.  Children are the most susceptible to the 
hepatitis B virus when infected during their first year, with 90% developing chronic 
infections.  Children between the ages one to four develop chronic infection at a rate of 
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30-50%.  Of the children infected, 25% develop liver cirrhosis or cancer and die in 
adulthood (WHO, 2012). 
 Vaccines can be created using recombinant gene technologies in which the 
vaccine can be made without a human or animal host and only includes the antigen 
needed.  Recombinant vaccines however, still have the potential for contamination from 
mammalian cell culture.  The development of a new type of vaccine that does not use 
animals or needs to be injected would be a benefit in terms of cost and administration 
hurdles. A plant-based oral vaccine is a reasonable alternative.  Plants produce proteins at 
a level high enough to vaccinate and plants are not susceptible to animal viruses that 
could infect the recipient.  Therefore, creating a plant based oral vaccine that is similar to 
current vaccines and eliminates the need for needles is possible.  
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CHAPTER 2 
Materials and Methods 
Genetic Materials 
 Two Stine Inbred lines 16038, a female stiff stalk type, and MBS5411, a 
Lancaster male type, were chosen because of high combining ability of the parents 
producing high yielding, uniform lines when crossed.  16038 is a high yield, and yellow 
dent variety.  MBS5411 is a high kernel weight, large ear diameter, yellow dent variety.  
Material expressing Hepatitis B surface antigen was created and obtained from the 
Applied Biotechnology Institute.  The lines used were crossed once to Hi-II and prior to 
starting the backcross program.  After each backcross, highest expressing ears were 
selected and carried forward into the next generation. The transgene was backcrossed 5 or 
6 times into both lines until approximately 99% commercial parent was obtained with a 
single gene coding for the vaccine present.  The 16038 line at backcross 4 (BC4) had 
sibling lines that were chosen to continue the program for further backcrossing and an 
accelerated hybrid, these lines are designated 16038-1 and 16038-2. To determine 
whether the gene coding for the vaccine is present the gene of interest is linked to 
herbicide resistance, with herbicide screening done each generation.  
 
Greenhouse Production 
 Backcrossing of the transgene into elite inbred lines was completed in 
greenhouses on the campus of California Polytechnic State University in San Luis 
Obispo, California.  Plants were grown in containers using a Foxfarm ocean forest 1.5 
cubic foot (cf) potting soil and 64 oz. of Aztec perlite. All Pots were autoclaved for 25 
minutes or bleached using a 10% solution to remove insects and pathogens. Amount of 
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seed planted per pot was determined by percent germination from the previous generation 
and number of ears needed at the end of the study.  Number of seeds germinated was 
recorded.  At the 3-to-4 leaf stage, plants were screened for the presence of the gene of 
interest utilizing the glufosinate-ammonium resistance screen.  Resistance screen in the 
greenhouse was done using a leaf paint technique so as to not kill the recurrent parent that 
are not resistant to the herbicide. The leaf paint technique is done by marking an X on a 
leaf and herbicide applied with a cotton swab.  Five days after painting, leaf results of the 
herbicide screen were taken by counting susceptible and resistant plants.  Susceptibility 
was determined by a browning of the leaf tip and necrosis across the painted section of 
the leaf (Figure 1).  No reaction to the herbicide was counted as resistance.   Susceptible 
plants were removed from pots and resistant plants were allowed to continue growth.   
     
Figure 1: Placement of the herbicide (left), a plant showing a susceptible response 
(middle), and a plant showing a resistant response (right) 
  
 Pollinations were done following the procedure described previously (Smith, 
2004).  Thirty two days after pollination the ear was harvested and dried in an oven at 
37.0° C until the seed was approximately 15% moisture.  After shelling the seed was sent 
to the lab for analysis.   
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Field Production 
 The field production of transgenic maize was done on an approximately one acre 
plot.  The maize was grown following conventional agriculture practices.  Percent 
germination for each line was determined shortly after emergence.  Herbicide screening 
was conducted on all transgenic lines with a backpack sprayer with 1.0% of active 
ingredient herbicide solution of glufosinate-ammonium at the three to four leaf stage.  
The herbicide screen was conducted with a backpack sprayer and shield to avoid spraying 
the recurrent parents, which are susceptible to the herbicide.  Plants susceptible to the 
herbicide were killed all resistant lines were assumed to contain the transgene and 
allowed to continue growth.  All plants containing the gene of interest were either 
backcrossed or selfed depending on their stage in the program.  Three backcrosses were 
completed in the field 16038-1-BC1, 16038-1-BC6, MBS5411-BC1 and all hybrids were 
grown in the field.  All pollinations were done according to the procedure described 
previously (Smith, 2004). Ears were harvested and dried to 12-14% moisture, and 
shelled.  Line weight was recorded and seed was sent to the lab for analysis of the HBsAg 
concentration.   
 
Creating Hybrids 
 The 16038 and MBS5411 lines containing the recombinant protein were crossed 
to create hybrid seed and then the hybrid seed was planted in the field and allowed to 
open pollinate creating hybrid grain.  CC140097 was a cross between 16038-2- BC5 and 
MBS5411-BC4.  CC140098 and CC140099 lines were both created by the cross 16038-
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1-BC6 and MBS5411-BC5.  Lines were split after analysis into a high expressing and 
low expressing bulk. Line CC140100 was the only line with one self and was a cross 
between 16038-2-BC5S1 and MBS5411-BC5.  Ears were allowed to dry-down on the 
plant, hand-harvested from the field, and analyzed.  
 
Pooled Seed Extracts 
  Seed from the backcross program was pooled from a single ear and 50 seeds 
were randomly selected.  For hybrid seed and hybrid grain all ears were bulked from a 
single line and the 50 seed pool was taken from the bulk.  Bulked seed was ground in a 
Speck Mill, Coffee Grinder for approximately 30 seconds.  100 mg of ground material 
was weighed in an extraction vial, a 3/8” ball bearing was placed on top of the maize, and 
1 ml of extraction buffer of (1mL phosphate buffer (PBS) and 1% Triton X) was added to 
each vial and capped.   The vial was then shaken for 20 seconds at a rate of 600 strokes 
per minute in a GENO/GRINDER 2000. Samples were then centrifuged using a Avanti J-
25 (Beckman Allegra, Brea Ca.) with a swinging bucket rotor JS-5.9 at 2,000 RCF (3280 
RPM) and 4°C for 13-17 minutes. 230-240 µl of the supernatant was removed and placed 
in a 96-well plate on ice. 
 
HBsAg Seed Expression 
 After each generation of seed was produced, the seed was analyzed to determine 
milligram of HBsAg per kilogram of maize material (mg/kg).  The testing procedure 
from the start of the project until 2013 has been described previously (Hayden, 2012a).  
In 2013 the procedure changed and the modifications are described by Hayden et al 
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(2014).  To account for any variation in the different procedures all the seed was rerun 
after the hybrid grain was harvested.   
 An ELISA assay was done using 100 milligrams (mg) of ground maize and 
extractions were done in 1 milliliter of PBS and 1% Triton-X 100. The ELISA was done 
with dilutions 1:250 as described by Hayden (2014).  The ELISA assay were measured 
with an induced chromophore response at 405nm (Hayden, 2012a). 
 
Seed Weights 
 25 seed weights were taken by counting out 25 seed from each bulked seed.  The 
seed was weighed in grams to the hundredths place.  Three different 25 seed samples 
were taken from each individual bulk and averaged. 
Statistics 
 Two-sample t-tests were conducted between each generation; significant 
differences between expression at different levels of backcrossing were identified. Two-
sample t-tests, were performed on Minitab to determine significant differences among 
HBsAg expression and 25 seed weights.  The alpha level for each test was 0.10.   
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CHAPTER 3  
Results  
  Backcross Expression and Seed Weights – Female 16038 Parent 
            The transformed line was backcrossed (BC) to the female parent 16038 for five or 
more generations depending on the line.  Herbicide screening was accomplished each 
generation, with hepatitis B surface antigen expression levels evaluated each generation. 
Expression levels from BC1 through BC4 were 89.0, 70.0, 37.0, and 130 mg/kg 
respectively (Table 1).  The BC4 line was backcrossed once more to 16038 to produce 
several sibling ears.  Two of the highest expressing sibling ears of the BC4 were chosen 
to continue the program but take different paths, these lines are designated 16038-1 and 
16038-2.  16038-1-BC5 had an expression of 129 mg/kg, which was backcrossed again 
and 16038-1-BC6 had an expression of 82 mg/kg.  16038-2-BC5 had an expression of 99 
mg/kg and the16038-2-BC5S1 had an expression of 222mg/kg. The only lines that 
showed a significant difference were between BC2 and BC3 (p = 0.067), BC3 and BC4 
(p = 0.078), BC5 and BC5S1 (p = 0.047), 16038-1-BC5 and 16038-1-BC6 (p = 0.004). 
 Seed weights from the backcrossed lines for BC1 through BC4 were 6.06, 2.80, 
3.68, and 3.71 grams respectively. 16038-1 BC5 had a seed weight of 3.53 grams and 
16038-1-BC6 had a seed weight of 5.23 grams.  16038-2-BC5 had a seed weight of 3.36 
grams and the 16038-2-BC5S1 seed weight of 5.19 grams. (Table 2). Significant 
differences were identified between 16038-1-BC1 and 16038-1-BC2 (p=0.001), 16038-1-
BC2 and 16038-1-BC3 (p =0.003), and 16038-1-BC5 and 16038-1-BC6 (p=0.004). A 
difference in weight between 16038-1-BC4 and 16038-2-BC5 (p=0.092), and 16038-2-
BC5 and 16038-2-BC5S1 (p=0.019).   
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 16038-1 16038-2 
BC1 89.0  
BC2 70.0  
BC3 37.0  
BC4 130  
BC5 129 99 
BC5S1 - 222 
BC6 82 - 
Table 1: Expression in mg/kg for each cross of the backcross program, and first self in 
the 16038 line.   
 
 16038-1 16038-2 
BC1 6.06  
BC2 2.8  
BC3 3.68  
BC4 3.71  
BC5 3.53 3.36 
BC6 5.23  - 
BC5S1 - 5.19 
Table 2: Seed weights in grams for each cross of the backcross program, and first self in 
the 16038 line. 
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Backcross Expression and Weight – Male Parent 
 The male parent MBS5411 was backcrossed for five generations.  Herbicide 
screening was accomplished each generation, with expression levels evaluated each 
generation. Expression levels from BC1 through BC4 were 33.3, 191, 240, 188, and 
173.5 mg/kg respectively (Table 3). The only significant difference in surface antigen 
expression was between BC1 and BC2 (p=0.043) at a p-value of 0.10.  All other 
backcrosses had no significant differences observed.   
 
 MBS5411 
BC1 33.3 
BC2 191 
BC3 240 
BC4 188 
BC5 173 
Table 3: Expression in mg/kg for each cross of the backcross program in the MBS5411 
line.     
 
 Seed weights from the backcrossed lines for MBS5411-BC1 through MBS5411-
BC5 were 5.58, 4.09, 5.41, 2.85, and 4.77 grams respectively (Table 4). Significant 
differences were found between all backcross generations, MBS5411-BC1 and 
MBS5411-BC2 (p=0.017), MBS5411-BC2 and MBS5411-BC3 (P=0.017), MBS5411-
BC3 and MBS5411-BC4 (p=0.002), and MBS5411-BC4 and MBS5411-BC5 (p=0.004). 
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 MBS5411 
BC1 5.58 
BC2 4.09 
BC3 5.41 
BC4 2.85 
BC5 4.77 
Table 4: Seed weights in grams for each cross of the backcross program in the MBS5411 
line. 
 
Hybrids 
 Four hybrid lines were developed to evaluate the hybrid performance at different 
levels of backcross generations.  The hybrid grain CC140097 had a total expression of 
99.2 mg/kg (Table 5) and a seed weight of 7.53 grams (Table 6). Hybrid CC140098, the 
high expressing bulk, expressed 129 mg/kg with a seed weight of 8.53 grams and 
CC140099, the low expressing bulk, expressed 80.8mg/kg with a seed weight of 7.75 
grams. Hybrid CC140100 expressed 82 mg/kg and seed weight was 8.09 grams.   
 
 CC140097 CC140098 CC140099 CC140100 
MBS5411 
PARENT 
188 173 173 173 
16038 
PARENT 
99 82 82 222 
HYBRID 99.2 129 80.8 81.1 
Table 5:  Expression of the parents and hybrid grain in mg/kg 
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 CC140097 CC140098 CC140099 CC140100 
MBS5411 
PARENT 
2.85 4.77 4.77 4.77 
16038 
PARENT 
3.35 5.23 5.23 3.84 
HYBRID 7.53 8.53 7.75 8.09 
Table 6:  Seed weights of the parents and hybrid grain expressed in grams per 25 seed 
 
Discussion 
Expression was expected to fluctuate at the start of the backcrossing program but 
was expected to stabilize as backcrossing progressed.  The hybrid grain was expected to 
increase in expression with increased seed size and increased positive alleles.  
Unfortunately none of the hybrid parents in all hybrid crosses in this study were 
homozygous for the transgene.  Backcross seed weight was expected to decrease as the 
backcross program progressed due to inbreeding while hybrid seed weight was expected 
to increase due to heterosis.  Some of the fluctuations in expression levels may appear 
larger than they are due to the inaccuracy of the assay used.  When tested the validated 
assay is ±25%. 
Female- 16038 
 The female line increased expression in the BC1 (89.0 mg/kg) and began to 
decrease in the BC2 and BC3 (70.0 mg/kg and 39.0 mg/kg respectively) before 
increasing in the BC4 (130.0 mg/kg) (Figure 2).  At the BC4 the line was split into two 
16038-1-BC5 and 16038-2-BC5.  Seed weights followed the expected pattern (Figure 3).  
All lines were grown in difference environments with the BC3 seed the only seed grown 
in the winter greenhouse which relied on a large amount of artificial light leading to an 
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alteration in growth, possibly contributing to the decreased expression.  However, in this 
study we did not attempt to quantify the variability in expression due to environment.  
 The BC5S1 was expected to increase as the number of positive alleles in the line 
increased, thus increasing the total expression level.  The BC5S1 was higher than BC5 
going from 99.0 mg/kg to 222.0 mg/kg.  However, average seed weight remained the 
same between the two lines.  
 
Figure 2:  Expression in the 16038 line expressed in mg/kg throughout the backcross. 
 
 
Figure 3:  Weight in grams of 25 seed throughout the breeding program for the 16038 
line. 
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Male-MBS5411 
 The highest expressing male line was BC3 at 240 mg/kg (Figure 4).  There was 
one significant difference in expression through the backcross program between BC1 
(33.3 mg/kg) and BC2 (191 mg/kg) at a p-value of 0.048.  The seed weight of the line 
throughout the backcross program tapers off as the backcrossing continued. The low 
expression for BC1 can be contributed its early stage in the backcross program. BC1 seed 
was grown in the field while all other backcrosses were done in the greenhouse.  BC1 
material is 50% Hi-II which does not perform well in less than ideal growing conditions 
and so fluctuations in temperature and water may have contributed to its lower 
expression.  
 
Figure 4:  Expression in MBS5411 expressed in mg/kg throughout the backcross program 
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Figure 5:  Weight in grams of 25 seed throughout the breeding program for MBS5411  
  
Hybrid program 
CC140097 
 Hybrid CC140097 was a cross of backcrossed individuals 16038-2-BC5 and 
MBS5411-BC4.  Expression of the grain from this seed was an average of its two parents 
while seed weight increased (Figure 10 and 11).  16038-2-BC5 contains 98% recurrent 
parent while MBS5411-BC4 contains 96% recurrent parent.   Seed weight increase was 
indicative of heterosis.  The expression within the hybrid was lower than expected.  This 
was likely due to a lack of homozygous parent lines leading to a segregating hybrid 
population. (Figure 11).   
 
CC140098 and CC140099 
 Both CC140098 and CC140099 are a cross of 16038-1-BC6 and MBS5411-BC5. 
16038-2-BC6 is 99% recurrent parent and MBS5411-BC5 is 98% recurrent parent.  The 
hybrid seed was split into two bulks; a high expressing bulk (CC140098) and a low 
expressing bulk (CC140099) (Figure 10).  The high expressing bulk expression was 
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higher than the 16038 parent where the low expressing line was almost equivalent to the 
16038 parent.  The high and low expressing bulks performed as anticipated and suggests 
that selection of hybrid seed for expression prior to planting may increase total HBsAg 
concentration in the hybrid grain. 
 
CC140100 
 Hybrid CC140100 is the only line with a self of the BC5.  A self increases the 
percentage of homozygous individuals.  With more homozygous individuals the dosage 
of the allele is increased.  The hybrid grain was created from 16038-2-BC5S1 and 
MBS5411-BC5 line.  The 16038-2-BC5S1 has 98% recurrent parent and MBS5411-BS5 
also has 98% recurrent parent.  Unfortunately both parents were higher expressing than 
the hybrid grain (Figure 6). The hybrid grain weight showed that there was hybrid vigor 
in the grain but expression did not increase (Figure 7).   
 
Figure 6: Expression levels for the lines that created the hybrid and the resulting hybrid 
grain in yellow. 
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Figure 7: Seed weights for the lines that created the hybrid and the resulting hybrid grain 
in yellow.  
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CHAPTER 4 
Conclusions 
 The 16038 line showed expression fluctuation throughout the backcross program.  
The variable expression levels in the 16038 leads to the conclusion that environment 
plays a large role in expression of the transgene.  Therefore more studies should be 
conducted to demonstrate if and how the environment influences expression.  The 
transgene appears to express better in the MBS5411 line than the 16038. Therefore, a 
new elite female line that is compatible to MBS5411 may help decrease the fluctuation 
among the female line and increase expression in that line.  With expression leveling off 
around backcross 5 and 6 further backcrossing may not be needed to increase expression 
and above 98% recurrent parent more backcrossing is not needed to improve agronomic 
traits.  The hybrid grain expression is consistent with the parent lines not being 
homozygous while seed weights indicate heterosis in all lines.  Further studies should be 
conducted with homozygous lines grown in the same environment to give a better 
indication of how genetics and the environment affect the expression of the hepatitis B 
surface antigen.  A true hybrid is expected to show increased expression due to higher 
dosage of the transgene.   
 
 
 
 
 
28 
 
References 
(2013) Food Allergy Research and Education. About food allergies: Other allergens. 
Food Allergy Research and Education. 
Armstrong C.L., Green C.E., Phillips R.L. (1991) Development and availability of 
germplasm with high Type II culture formation response. 
Becker G.S., Vogt D. (2005) Regulation of Plant-Based Pharmaceuticals, The Library of 
Congress. 
FDA. (1989) Highlights of Prescribing Information. Retrieved from: 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPro
ducts/UCM224503.pdf 
Giudice E.L., Campbell J.D. (2006) Needle-free Vaccine Delivery, Advanced Drug 
Delivery Reviews. pp. 68-89. 
Hayden C.A., Egelkrout E.M., Moscoso A.M., Enrique C., Keener T.K., Jimenez-Flores 
R., Wong J.C., Howard J.A. (2012a) Production of highly concentrated, heat-
stable hepatitis B surface antigen in maize. Plant Biotechnology Journal 10:979-
984. DOI: 10.1111/j.1467-7652.2012.00727.x. 
Hayden C.A., Streatfield S.J., Lamphear B.J., Fake G.M., Keener T.K., Walker J.H., 
Clements J.D., Turner D.D., Tizard I.R., Howard J.A. (2012b) Bioencapsulation 
of the hepatitis B surface antigen and its use as an effective oral immunogen. 
Vaccine 30:2937-2942. DOI: 10.1016/j.vaccine.2012.02.072. 
Hayden CA, Smith EM, Turner DD, Keener TK, Wong JC, Walker JH, Tizard IR, 
Jimenez-Flores R, Howard JA (2014). Supercritical fluid extraction provides an 
enhancement to the immune response for orally-delivered hepatitis B surface 
antigen. Vaccine , doi: 10.1016/j.vaccine.2014.01.037 
Howard J.A. (2005) Commercialization of Biopharmaceutical and Bioindustrial Proteins 
from Plants, Crop Science. pp. 468-472. 
Kirk D.D., McIntosh K., Walmsley A.M., Peterson. R.K.D. (2005) Risk Analysis for 
Plant-made Vaccines, Transgenic Research. pp. 449-462. 
Kwon S.Y., Lee C.H. (Epidemiology and prevention of hepatitis B virus infection) 2011, 
Journal of Viral Hepatitis. pp. 87-95. 
 
29 
 
Lamphear B.J., Streatfield S.J., Jilka J.M., Brooks C.A., Barker D.K., Turner D.D., 
Delaney D.E., Garcia M., Wiggins B., Woodard S.L., Hood E.E., Tizard I.R., 
Lawhorn B., Howard J.A. (2002) Delivery of subunit vaccines in maize seed. 
Journal of Controlled Release 85:169-180. DOI: 
http://dx.doi.org/10.1016/S0168-3659(02)00282-1. 
Merck. (1983) Highlights of Prescribing Information. Retrieved from: 
http://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi
.pdf 
Nap J.-P., Metz P.L., Escaler M., Conner A.J. (2003) The release of genetically modified 
crops into the environment, The Plant Journal. 
Offit, P. 2013. Can people with yeast allergies get vaccines? The Children's Hospital of 
Philadelphia. 
Ramessar K., Sabalza M., Capell T., Christou P. (2008) Maize plants: An ideal 
production platform for effective and safe molecular pharming, Plant Science. 
pp. 409-419. 
Rybicki E.P. (2009) Plant-produced Vaccines: Promise and Reality, Drug Discovery 
Today. pp. 16-24. 
Shchelkunov S., Shchelkunova G. (2010) Plant-based Vaccines Against Human 
Hepatitis B Virus, Expert Review of Vaccines. pp. 947-955. 
Smith W., Betran J., Runge E. (2004) Corn: Origin, History, Technology, and 
Production.  John Wiley & Sons. Pg. 335-356. 
Streatfield S.J., Jilka J.M., Hood E.E., Turner D.D., Bailey M.R., Mayor J.M., Woodard 
S.L., Beifuss K.K., Horn M.E., Delaney D.E., Tizard I.R., Howard J.A. (2001) 
Plant-based Vaccines: Unique Advantages, Vaccine. pp. 2742-2748. 
Streatfield S.J., Mayor J.M., Barker D.K., Brooks C., Lamphear B.J., Woodard S.L., 
Beifuss K.K., Vicuna D.V., Massey L.A., Horn M.E., Delaney D.E., Nikolov 
Z.L., Hood E.E., Jilka J.M., Howard J.A. (2002) Development of an Edible 
Subunit Vaccine in  Corn Against Enterotoxigenic Strains of Escherichia Coli, In 
Vitro Cellular & Amp. pp. 11-17. 
W.H.O. (2012) Hepatitis B fact sheet, Online. 
Wen S.X., Teel L.D., Judge N.A., O'Brien A.D. (2006) A plant-based oral vaccine to 
protect against systemic intoxication by Shiga toxin type 2. Proceedings of the 
National Academy of Sciences of the United States of America 103:7082-7087. 
DOI: 10.1073/pnas.0510843103. 
 
